About Censa Pharmaceuticals
Censa Pharmaceuticals is a Healthcare company based in Cambridge (United States) founded in 2015, and was acquired by PTC Therapeutics in May 2020. Drugs for Tetrahydrobiopterin deficiency and rare CNS disorders are developed. Censa Pharmaceuticals has raised $3.01 million across 2 funding rounds from investors including PTC Therapeutics. The company has 2 employees. Its focus areas include Life Sciences, Rare Diseases, Drugs and CNS. Its legal entity is CENSA PHARMACEUTICALS INC. Its competitors include Harmony Biosciences, QurAlis and Passage Bio; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2015 in Cambridge, United States, Censa Pharmaceuticals operates in the pharmaceutical sector at the preclinical stage. Drugs are developed for rare central nervous system disorders, emphasizing issues in neurotransmitter degradation and synthesis. The lead candidate, CNSA-001, advances through discovery for Tetrahydrobiopterin deficiency, which involves shortages of BH4 and altered phenylalanine levels. FDA and EMA approvals are targeted within four years, while parallel programs address broader CNS conditions.
- Headquarters Cambridge, United States
- Employees 2
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website censapharma.com
- Social LinkedIn
- Acquired by PTC Therapeutics (May 2020)
- Legal Name Censa Pharmaceuticals Inc
- Total Equity Funding$3.01M (USD)
in 2 rounds
- Latest Funding Round$1.5M (USD), Seed
Nov 2017
- Investors
- Employee Count2
- Acquired byPTC Therapeutics
(May 2020)
Funding Insights of Censa Pharmaceuticals
Censa Pharmaceuticals has successfully raised a total of $3.01M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $1.5 million completed in November 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.01M
- Total Rounds 2
- Last Round Seed — $1.5M
- First Round $1.51M
(Apr 2016)
All 2 funding rounds of Censa Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2017 | $1.5M | Seed | – | – | – |
| Apr 2016 | $1.51M | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in Censa Pharmaceuticals
Censa Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include PTC Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Small molecule drugs for rare diseases are developed. | 1998 | ptcbio.com | South Plainfield, United States |
Investor details for Censa Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Censa Pharmaceuticals
4 dated milestones of Censa Pharmaceuticals across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Censa Pharmaceuticals is founded.
- Funding First funding round of $1.5M.
- Funding Latest funding round, Seed, of $1.5M.
- Exit Acquired by PTC Therapeutics.
Competitors of Censa Pharmaceuticals
Censa Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Harmony Biosciences, QurAlis and Passage Bio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| harmonybiosciences.com | 2017 | Plymouth Meeting, United States | $345M | 246 | Developer of therapeutics for rare neurological diseases | |
| quralis.com | 2016 | Cambridge, United States | $155.45M | 38 | Drugs and CSF devices are developed for ALS treatment. | |
| passagebio.com | 2017 | Philadelphia, United States | $225.5M | 58 | Gene therapies for CNS rare diseases are developed. |
Detailed competitors of Censa Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
3 companies that operate in the same segment as Censa Pharmaceuticals (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Censa Pharmaceuticals
Complete news archive for Censa Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Censa Pharmaceuticals
Censa Pharmaceuticals was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Censa Pharmaceuticals is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Censa Pharmaceuticals is a funded company, having raised a total of $3.01M across 2 funding rounds to date. The company's 1st funding round was a Seed of $1.51M, raised on Apr 2016.
Censa Pharmaceuticals has 2 employees.
Founded in 2015 in Cambridge, United States, Censa Pharmaceuticals operates in the pharmaceutical sector at the preclinical stage. Drugs are developed for rare central nervous system disorders, emphasizing issues in neurotransmitter degradation and synthesis. The lead candidate, CNSA-001, advances through discovery for Tetrahydrobiopterin deficiency, which involves shortages of BH4 and altered phenylalanine levels. FDA and EMA approvals are targeted within four years, while parallel programs address broader CNS conditions.
Censa Pharmaceuticals's top competitors include Harmony Biosciences, QurAlis and Passage Bio.
Censa Pharmaceuticals has 1 investor. Key investors include PTC Therapeutics.
Censa Pharmaceuticals operates through Censa Pharmaceuticals Inc.
Yes. Censa Pharmaceuticals was acquired by PTC Therapeutics in May 2020.